Find a Trial

Trial Results


23 protocol(s) meet the specified criteria
CTO-17-101OPEN TO ACCRUAL
Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
CTO-A011801OPEN TO ACCRUAL
THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB
CTO-BRE18-334OPEN TO ACCRUAL
A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)
CTO-BTCRC-BRE18-337OPEN TO ACCRUAL
Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337
CTO-CTMX-2009-002OPEN TO ACCRUAL
A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast Cancer (CTMX-2009-002)
CTO-EA1181OPEN TO ACCRUAL
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
CTO-EAZ171OPEN TO ACCRUAL
Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women
CTO-IUSCC-0715OPEN TO ACCRUAL
Pilot study of a mobile health strategy to improve medication adherence in breast cancer survivors receiving aromatase inhibitors
CTO-IUSCC-0718OPEN TO ACCRUAL
A quality improvement project to increase knowledge and referrals to the IU breast cancer prevention program
CTO-M19-345OPEN TO ACCRUAL
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors
IUCRO-0209OPEN TO ACCRUAL
The Susan G. Komen Tissue Bank at the IU Simon Cancer Center: A Collection and Storage of Biological Specimens Intended for use in the Elucidation of Breast Carcinogenesis
IUSCC-0630OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY AND REGISTRY FOR INFLAMMATORY BREAST CANCER
IUSCC-0649OPEN TO ACCRUAL
Functional and Neurochemical Substrates of Chemotherapy-Related Cognitive Deficits
IUSCC-0659OPEN TO ACCRUAL
Assessing tobacco use and cessation support among patients with non-tobacco related cancers
IUSCC-0678OPEN TO ACCRUAL
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
IUSCC-0706OPEN TO ACCRUAL
Facilitating Adaptive Coping with Fear of Recurrence Among Breast Cancer Survivors: A Three-Arm Randomized Controlled Trial (FACing Fear)
J11155OPEN TO ACCRUAL
Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer
J13104OPEN TO ACCRUAL
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)
NURS-IIR-IUSCC-0748OPEN TO ACCRUAL
Biobehavioral correlates of cancer-related cognitive dysfunction and its co-occurring symptoms
RADY-ECOG-WESTPHAL-EA1151OPEN TO ACCRUAL
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) EA1151
RADY-GU-SAYKIN-TLCOPEN TO ACCRUAL
Older Breast Cancer Patients: Risk for Cognitive Decline
RADY-IIR-CBTOPEN TO ACCRUAL
Mobile Device CBT for Chemotherapy-Related Cognitive Dysfunction: A Multi-Center Randomized Controlled Trial
TBCRC042OPEN TO ACCRUAL
A Randomized Phase II Window-of-opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions